Novavax stock is soaring on news the FDA set a deadline by which to approve or reject its COVID-19 vaccine.
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Pfizer stock is struggling to retake its 200-day line despite promising updates in cancer treatment. Is PFE stock now a sell?